GILD vs REGN
GILD and REGN side by side — valuation & fundamentals (public data).
Key statistics
| Metric | GILDGILEAD SCIENCES, INC. | REGNREGENERON PHARMACEUTICALS, INC. |
|---|---|---|
| Market cap | $211.34B | — |
| P/E (TTM) | 25.1 | 21.3 |
| P/B | 16.21 | — |
| P/S | 7.1x | — |
| Dividend yield | 1.89% | — |
| Revenue | $30.99B(TTM) | $16.90B(TTM) |
| Revenue growth (YoY) | 2.4% | 1.0% |
| Net income | -$3.86B(TTM) | $4.82B(TTM) |
| Earnings growth (YoY) | 1672.9% | 2.1% |
| EPS, diluted | $-3.13(TTM) | $45.24(TTM) |
| EBIT margin | 34.0% | 24.9% |
| ROE | 65.3% | 13.4% |
| ROIC | 25.7% | 9.2% |
| 1y total return | +42.7% | +47.6% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: GILD vs REGN
| Metric | GILD | REGN |
|---|---|---|
| End value | $29.3K | $27.8K |
| Total return | +192.6% | +177.8% |
| CAGR | +10.9% | +10.4% |
| Volatility | 25.6% | 32.3% |
| Sharpe | 0.37 | 0.34 |
| Sortino | 0.55 | 0.50 |
| Max drawdown | -30.5% | -59.7% |
Based on 2600 common trading days, 2016-06-30 → 2026-11-02 · risk-free 4.16% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)